NHS (N-hydroxysuccinimide) functionalized magnetic material as well as preparation method and application thereof
By mixing the magnetic core material with NHS and diamine compounds with diisocyanate compounds in DMF, the NHS functionalized magnetic material is prepared by oscillating reaction, and the functional group distribution control in the prior art is solved by modifying cystamine, acid anhydride and EDC/NHS. and reactivity issues, efficient magnetic material synthesis and capture efficiency is achieved.
Patent Information
- Application Number
- CN202411129311.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, when synthesizing functionalized magnetic materials, it is difficult to control the spatial distribution and reactivity of functional groups, and a large amount of EDC/NHS reagent is required during batch synthesis, and it is difficult to achieve efficient covalent modification under laboratory conditions.
The magnetic core material, NHS and diamine-containing compounds are mixed with diisocyanate compounds in DMF to prepare NHS functionalized magnetic materials through oscillation reactions, and the formation of magnetic probes is achieved using cystamine, anhydride and EDC/NHS modification processes. and sample capture.
It realizes the easy and controllable synthesis of NHS functional magnetic materials, with excellent magnetic separation performance and uniformity, improves capture efficiency, reduces catalyst use, and simplifies the synthesis process.
Smart Images

Figure CN119016034A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of metabolite analysis, and more particularly to an NHS functionalized magnetic material and a preparation method and application thereof. Background Art
[0002] Polymer materials are biocompatible, highly efficient, and porous, and can be constructed with desired functional properties, and have been widely used to separate and analyze target molecules from mixed samples. The inherent magnetism of magnetic nanoparticles (MNPs) makes separation operations very convenient (e.g., by magnetic decantation), eliminating the centrifugation or flocculation process usually required to recover non-magnetic materials. The functional group diversity and loading capacity of magnetic polymer materials can be greatly increased by introducing dendrimers or polymer shells on the surface of MNPs. The application of magnetic polymer materials with unique properties in biomedical research has improved their performance.
[0003] Currently, functional groups such as -OH, -NH2 and -COOH can be directly introduced on the surface of magnetic materials by coating MNPs with silica (SiO2), polydopamine and polyacrylic acid (PAA). However, it should be noted that the spatial distribution is difficult to control and the reactivity of functional groups such as hydroxyl groups of specific linkers is also limited. In addition, due to steric hindrance, it is difficult to effectively covalently bond biomacromolecules to magnetic materials through post-synthetic modification strategies. Chemical selective probe labeling strategies have greatly promoted the study of proteomics and genomics and have shown great potential in the in-depth description of metabolomics. In addition, chemical probes immobilized on the surface of magnetic materials provide a rapid and powerful analytical tool for identifying labeled metabolites in complex matrices. Therefore, the preparation of functionalized magnetic materials with rich active groups is very important for rapid surface modification and efficient extraction of target molecules.
[0004] NHS active esters can quickly couple ligands such as amino and sulfhydryl groups and can be widely used in the fields of chemistry and biology. NHS active esters are usually generated by carboxyl groups in the presence of EDC / NHS, so their density is affected by the number of carboxyl groups on the surface of the material and the reaction efficiency of the crosslinker. The existing technology introduces NHS active groups when synthesizing polymer beads, but this preparation method requires the consumption of a large amount of EDC / NHS reagents and is difficult to synthesize in batches under laboratory conditions.
[0005] Therefore, how to develop a fast and simple NHS functionalized magnetic material and its preparation method and application is an urgent problem to be solved by technicians in this field. Summary of the invention
[0006] In view of this, the present invention provides an NHS functionalized magnetic material and a preparation method and application thereof.
[0007] In order to achieve the above object, the present invention adopts the following technical solution:
[0008] A method for preparing an NHS functionalized magnetic material comprises the following steps:
[0009] (1) adding a magnetic core material, NHS (N-hydroxysuccinimide) and a diamine-containing compound into DMF (N,N-dimethylformamide), and then adding a solution containing a diisocyanate compound to mix to obtain a mixture;
[0010] In the above mixture, the concentration of the magnetic core material is 0.25-4 mg / mL, the concentration of NHS is 0.05-0.2 mol / L, the molar ratio of the diisocyanate compound to the diamine compound is (1-4):1, preferably, the molar ratio of the diisocyanate compound to the diamine compound is 3:1;
[0011] (2) The mixture is subjected to an oscillation reaction for 0.5-24 h, the product is separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material.
[0012] Furthermore, the diamine-containing compound is one or more of ethylenediamine, propylenediamine, butylenediamine or hexamethylenediamine.
[0013] Furthermore, the diisocyanate-containing compound is one or more of hexamethylene diisocyanate, 1,4-diisocyanate butane, 4,4'-methylene diphenyl diisocyanate, m-xylyl diisocyanate or 1,4-phenylene diisocyanate.
[0014] Furthermore, the magnetic core material is one or more of ferroferric oxide nanoparticles, ferroferric oxide nanoparticles coated with silicon dioxide, ferroferric oxide nanoparticles modified by amino groups or ferroferric oxide nanoparticles modified by carboxyl groups.
[0015] Furthermore, the particle size of the magnetic core material is 200-500nm.
[0016] Furthermore, the oscillation reaction time is 0.5-3h, preferably, the oscillation reaction time is 1h, the oscillation reaction temperature is 25°C, and the oscillation frequency is 1500rpm.
[0017] The invention also provides an NHS functionalized magnetic material prepared by the method.
[0018] The present invention also provides an application of the NHS functionalized magnetic material in capturing carboxyl compounds in a sample.
[0019] Furthermore, the use of the above-mentioned NHS functionalized magnetic material in capturing carboxyl compounds in a sample comprises the following steps:
[0020] 1) Cystamine modification: Cystamine dihydrochloride, MES buffer containing Tween-20 and triethylamine are mixed to obtain a cystamine solution, the NHS functionalized magnetic material is dispersed in the cystamine solution, shaken, and washed twice with water and DMF to obtain a cystamine-modified magnetic material;
[0021] 2) Anhydride modification: the cystamine-modified magnetic material was dispersed in caron anhydride solution, shaken, and washed with DMF three times;
[0022] 3) EDC / NHS activation: Add a mixed solution of EDC / NHS containing DMF or dichloromethane to the anhydride-modified magnetic material, shake at room temperature, and wash with DMF three times;
[0023] 4) Diamine modification: the EDC / NHS activated magnetic material is added to DMF for suspension, and then a diamine compound solution containing DMF as solvent is added, and the reaction is shaken at room temperature, and washed twice with water, an acetonitrile aqueous solution containing 0.2 wt% ammonia and 50% acetonitrile volume concentration, and DMF to obtain a magnetic probe;
[0024] 5) dispersing the magnetic probe in dimethyl sulfoxide and mixing it with the sample to be tested, adding DIPEA and HOBT solutions and mixing, then adding HATU solution and mixing thoroughly, shaking, and then washing twice with 50% acetonitrile aqueous solution and pure acetonitrile respectively;
[0025] 6) The magnetic probe was redispersed in a 50% acetonitrile aqueous solution, and then a DTT aqueous solution was added. The target analyte, i.e., the carboxyl compound, was released after shaking. The supernatant was collected by magnetic separation, centrifuged, and then subjected to UPLC-Q-TOF-MS / MS detection.
[0026] Further, in step 1), the concentration of cystamine dihydrochloride in the cystamine solution is 0.5-1M, the volume concentration of triethylamine is 5-20%; the concentration of MES buffer is 0.1M, the oscillation reaction time is 5-60min, the oscillation reaction temperature is 25°C, and the oscillation frequency is 1500rpm;
[0027] In step 2), the concentration of the caron anhydride solution is 0.01-5M, the oscillation reaction time is 5-24h, the oscillation reaction temperature is 25-50°C, and the oscillation frequency is 1500rpm;
[0028] In step 3), the concentrations of EDC and NHS in the EDC / NHS mixed solution are 0.01-0.1 M, respectively, and the reaction is oscillated at room temperature for 10-24 h at a frequency of 1500 rpm;
[0029] In step 4), the concentration of the diamine-containing compound is 4 M, and the reaction is oscillated at room temperature for 3-90 min at a frequency of 1500 rpm;
[0030] In step 5), the concentration of the HOBT solution is 0.05 to 20 mM, preferably 0.1 to 2 mM, the concentration of the HATU solution is 0.05 to 20 mM, preferably 0.1 to 2 mM, the oscillation reaction time is 1 h, the oscillation reaction temperature is 25° C., and the oscillation frequency is 1500 rpm;
[0031] In step 6), the concentration of the DTT aqueous solution is 0.1 M, the oscillation reaction time is 15 min, the oscillation reaction temperature is 25° C., and the oscillation frequency is 1500 rpm.
[0032] The beneficial effects of the present invention are as follows: the present invention can easily and controllably synthesize NHS functionalized magnetic material PMMPs, which is not only simple and convenient to synthesize, but also easy to obtain raw materials, and PMMPs have excellent magnetic separation performance, similar particle size and fluffy non-spherical structure, and the synthesized PMMPs have good uniformity. Since primary amines have high nucleophilicity, when reacting with isocyanates, the reaction activity of amines is much higher than that of water and primary alcohols, and therefore, the synthesis of diamine-diisocyanate polyurea can be carried out at room temperature without the use of a catalyst, and the application of NHS functionalized magnetic materials in capturing carboxyl compounds in samples can improve the capture efficiency. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 A schematic diagram of the chemical reaction principle for preparing NHS functionalized magnetic materials (magnetic polyurea microspheres) according to the present invention;
[0034] Figure 2 Schematic diagram of the chemical selective extraction principle of analyzing carboxyl-containing compounds using cystamine-modified magnetic polyurea microspheres of the present invention.
[0035] Figure 3 This is a scanning electron microscope image of the magnetic polyurea microspheres of Examples 1-5;
[0036] Figure 4 Among them, A is a bar graph of the peak area of the target analyte deoxycholic acid detected by LC-MS in Application Example 1-5, B is a bar graph of the peak area of the target analyte deoxycholic acid detected by LC-MS in Application Examples 2-1 and 6-11, C is a bar graph of the peak area of the target analyte deoxycholic acid detected by LC-MS in Application Examples 3-1 and 12-16, and D is a bar graph of the peak area of the target analyte deoxycholic acid detected by LC-MS in Application Examples 4-1 and 17-20.
[0037] Figure 5In the figure, A is the hysteresis curve of MNPs and PMMPs, B is the fluorescence microscopy image of FITC-labeled cystamine-modified PMMP, C is the laser confocal micrograph of FITC-labeled cystamine-modified PMMP, and D is the quantitative analysis of NHS esters on the surface of PMMPs by LC-MS analysis on a HILIC column. DETAILED DESCRIPTION
[0038] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0039] The particle size of the ferrosoferric oxide nanoparticles used in Example 1-20 is 300 nm.
[0040] Example 1
[0041] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0042] (1) 1 mg of ferrosoferric oxide nanoparticles (MNPs), 11.5 mg of N-hydroxysuccinimide (NHS) and 1 μL of propylenediamine (DAP) were added to 0.6 mL of DMF, and then 0.4 mL of a 1.5% by volume solution of hexamethylene diisocyanate (HDI) was added and mixed (the molar ratio of hexamethylene diisocyanate to propylenediamine was 3:1), and the solvent of the hexamethylene diisocyanate solution was N,N-dimethylformamide (DMF), to obtain a mixture;
[0043] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, namely, magnetic polyurea microspheres (PMMPs).
[0044] Example 2
[0045] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0046] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 0.4 mL of a 1.5% by volume 1,4-diisocyanate butane (DICB) solution was added and mixed (the molar ratio of 1,4-diisocyanate butane to propylene diamine compound was 3:1), and the solvent of the 1,4-diisocyanate butane solution was DMF, to obtain a mixture;
[0047] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0048] Example 3
[0049] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0050] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 0.4 mL of a solution containing 16.2 mg of 4,4'-methylene diphenyl diisocyanate (4,4'-MDI) was added and mixed (the molar ratio of 4,4'-methylene diphenyl diisocyanate to propylene diamine compound was 3:1), and the solvent of the 4,4'-methylene diphenyl diisocyanate solution was DMF, to obtain a mixture;
[0051] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0052] Example 4
[0053] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0054] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 0.4 mL of a 1.5% volume fraction of m-xylyl diisocyanate (XDI) solution was added and mixed (the molar ratio of m-xylyl diisocyanate to propylene diamine compound was 3:1), and the solvent of the m-xylyl diisocyanate solution was DMF, to obtain a mixture;
[0055] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0056] Example 5
[0057] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0058] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 0.4 mL of a solution containing 5.76 mg of 1,4-phenylene diisocyanate (PPDI) was added and mixed (the molar ratio of 1,4-phenylene diisocyanate to propylene diamine was 3:1), and the solvent of the 1,4-phenylene diisocyanate solution was DMF, to obtain a mixture;
[0059] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0060] like Figure 3 As shown, Examples 1-3 can synthesize magnetic polyurea microspheres with relatively sparse structures, the fibrous micelles synthesized in Example 4 cannot encapsulate MNPs, and the product of Example 5 only has attached ferrosoferric oxide nanoparticles.
[0061] Example 6
[0062] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0063] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 0.4 mL of a 1% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of the hexamethylene diisocyanate to the propylene diamine compound was 2:1), to obtain a mixture;
[0064] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0065] Example 7
[0066] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0067] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 400 μL of a 0.625% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of hexamethylene diisocyanate to propylene diamine was 1.25:1), to obtain a mixture;
[0068] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0069] Example 8
[0070] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0071] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 400 μL of a 0.75% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of hexamethylene diisocyanate to propylene diamine was 1.5:1), to obtain a mixture;
[0072] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0073] Example 9
[0074] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0075] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 400 μL of a 0.875% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of hexamethylene diisocyanate to propylene diamine was 1.75:1), to obtain a mixture;
[0076] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0077] Example 10
[0078] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0079] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 Ml of DMF, and then 400 μL of a 1.25% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of hexamethylene diisocyanate to propylene diamine was 2.5:1), to obtain a mixture;
[0080] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0081] Embodiment 11
[0082] The preparation method of NHS functionalized magnetic material comprises the following steps:
[0083] (1) 1 mg of ferrosoferric oxide nanoparticles, 11.5 mg of NHS and 1 μL of propylene diamine were added to 0.6 mL of DMF, and then 400 μL of a 2% by volume solution of hexamethylene diisocyanate was added and mixed, wherein the solvent of the hexamethylene diisocyanate solution was DMF (the molar ratio of hexamethylene diisocyanate to propylene diamine was 4:1), to obtain a mixture;
[0084] (2) The mixture was subjected to an oscillation reaction for 1 h at a temperature of 25° C. and a frequency of 1500 rpm. The product was separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material, i.e., magnetic polyurea microspheres.
[0085] Example 12
[0086] Compared with Example 1, the oscillation reaction time was 0.25 h, and the other steps and parameters remained unchanged.
[0087] Embodiment 13
[0088] Compared with Example 1, the oscillation reaction time was 0.5 h, and the other steps and parameters remained unchanged.
[0089] Embodiment 14
[0090] Compared with Example 1, the oscillation reaction time was 3 h, and the other steps and parameters remained unchanged.
[0091] Embodiment 15
[0092] Compared with Example 1, the oscillation reaction time was 5 h, and the other steps and parameters remained unchanged.
[0093] Example 16
[0094] Compared with Example 1, the oscillation reaction time was 7 h, and the other steps and parameters remained unchanged.
[0095] Embodiment 17
[0096] Compared with Example 1, 5.75 mg NHS (NHS concentration 0.05 M) was added, and other steps and parameters remained unchanged.
[0097] Embodiment 18
[0098] Compared with Example 1, 8.63 mg NHS (NHS concentration 0.075 M) was added, and other steps and parameters remained unchanged.
[0099] Embodiment 19
[0100] Compared with Example 1, 17.3 mg NHS (NHS concentration 0.15 M) was added, and other steps and parameters remained unchanged.
[0101] Embodiment 20
[0102] Compared with Example 1, 23 mg NHS (NHS concentration 0.2 M) was added, and other steps and parameters remained unchanged.
[0103] Application Example 1-5 used the cecal contents extract of rat No. 1 for the experiment.
[0104] Application Examples 2-1 and 6-11 used the cecal content extract of No. 2 rat for the experiments.
[0105] Application Examples 3-1 and 12-16 used the cecal content extract of rat No. 3 for the experiments.
[0106] Application Examples 4-1 and 17-20 used the cecal content extract of rat No. 4 for the experiments.
[0107] The contents of components in the cecal content extracts of different rats were different.
[0108] Application Example 1
[0109] The application of NHS functionalized magnetic materials in capturing carboxyl compounds in a sample comprises the following steps:
[0110] 1) Cystamine modification: 2.25 g of cystamine dihydrochloride, 9 mL of 0.1 M MES buffer (containing 0.5% Tween-20) and 1 mL of triethylamine were mixed to obtain a 1 M cystamine solution, 50 mg of the magnetic polyurea microspheres obtained in Example 1 were dispersed in 10 mL of the cystamine solution, and the mixture was shaken at 25° C. for 30 minutes at a frequency of 1500 rpm, collected, and rinsed twice with water and DMF (N,N-dimethylformamide) to obtain a cystamine-modified magnetic material;
[0111] 2) Anhydride modification: the cystamine-functionalized NHS-functionalized magnetic material was dispersed in 10 mL of a 1 M carboxylic anhydride DMF solution, shaken at 50° C. for 10 hours at a shaking frequency of 1500 rpm, magnetically separated, washed with DMF and DMSO (dimethyl sulfoxide), and then redispersed in DMSO for later use;
[0112] 3) EDC / NHS activation: 10 mL of a DMF-based EDC / NHS mixed solution was added to the anhydride-modified magnetic material, where the concentrations of EDC and NHS in the EDC / NHS mixed solution were 0.1 M, respectively. The mixture was shaken at room temperature for 10 h at a frequency of 1500 rpm, and washed with DMF three times.
[0113] 4) Diamine modification: The EDC / NHS-activated magnetic material was suspended in 2 mL of DMF, and then a 4 M diamine compound solution in DMF was added, and the reaction was carried out at room temperature for 30 min at a shaking frequency of 1500 rpm. The magnetic probe was washed twice with water, 50% acetonitrile aqueous solution (containing 0.2% ammonia water), and DMF to obtain a magnetic probe;
[0114] 5) 2 mg of the magnetic probe was dispersed in 425 μL DMSO and mixed with 50 μL of rat cecal content extract (the rat cecal content extract was obtained by ultrasonic extraction of rat cecal content with acetonitrile), 1 μL of DIPEA (N, N-diisopropylethylamine) and 10 μL of a freshly prepared 0.1 M HOBT (1-hydroxybenzotriazole) solution with DMSO as the solvent were added and mixed, and then 10 μL of a freshly prepared 0.1 M HATU (2-(7-azobenzotriazole)-N, N, N', N'-tetramethyluronium hexafluorophosphate) solution with DMSO as the solvent was quickly added and mixed thoroughly, the mixture was shaken at 25° C. for 1 hour at a shaking frequency of 1500 rpm, and then washed twice with a 50% acetonitrile aqueous solution and a pure acetonitrile aqueous solution, respectively;
[0115] 6) Redispersed in 985 μL of 50% acetonitrile aqueous solution, then added 15 μL of 0.1M DTT (dithiothreitol) aqueous solution, and released the target analyte deoxycholic acid and its derivatives after oscillation at 25°C for 15 minutes, with an oscillation frequency of 1500 rpm. The supernatant was collected by magnetic separation, centrifuged at 13000 rpm for 15 minutes at 4°C, and then subjected to UPLC-Q-TOF-MS / MS detection.
[0116] Table 1: Application Example 1 QTOF-UPLC-MS combined with magnetic probe to detect some carboxyl compounds from rat cecal contents
[0117] m / z theoretical value m / z detection value Error ppm 1 Formic acid 300.1387 300.1387 0.0 2 Acetic acid 314.1544 314.1571 8.6 3 Propionic acid 328.1700 328.1696 1.2 4 Butyric acid 342.1857 342.1839 5.3 5 Isobutyric acid 342.1857 342.1839 5.3 6 Valeric acid 356.2013 356.2034 5.9 7 Isovalerate 356.2013 356.2034 5.9 8 Hexanoic acid 370.2170 370.2184 3.8 9 Heptanoic acid 384.2326 384.2356 7.8 10 Lithocholic acid 630.4310 630.4313 0.5 11 cholic acid 662.4208 662.4171 5.6 12 Chenodeoxycholic acid 646.4259 646.4247 1.9 13 Lithocholic acid 630.4310 630.4313 0.5 14 Deoxycholic acid 646.4259 646.4247 1.9 15 Hyodeoxycholic acid 646.4259 646.4247 1.9 16 Hognobular acid 662.4208 662.4171 5.6 17 β-Muricholic acid 662.4208 662.4247 5.8 18 7-Methyl-cholic acid 676.4365 676.4374 1.4
[0118] Application Example 2
[0119] Compared with Application Example 1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 2, and the other steps and parameters remained unchanged.
[0120] Application Example 3
[0121] Compared with Application Example 1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 3, and the other steps and parameters remained unchanged.
[0122] Application Example 4
[0123] Compared with Application Example 1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 4, and the other steps and parameters remained unchanged.
[0124] Application Example 5
[0125] Compared with Application Example 1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 5, and the other steps and parameters remained unchanged.
[0126] like Figure 4 As shown in A, according to Application Examples 1-5, the labeled deoxycholic acid is released from the magnetic polyurea microspheres and analyzed by LC-MS. The coupling modification ability of the magnetic polyurea microspheres synthesized with hexamethylene diisocyanate and 1,4-diisocyanate butane is much higher than that of aromatic diisocyanate, among which the magnetic polyurea microspheres synthesized with hexamethylene diisocyanate have the best performance.
[0127] Application Example 2-1
[0128] Compared with Application Example 1, the rat cecal content extract No. 1 in Application Example 1 is replaced with the rat cecal content extract No. 2, and the other steps and parameters remain unchanged.
[0129] Application Example 6
[0130] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 6, and the other steps and parameters remained unchanged.
[0131] Application Example 7
[0132] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 7, and the other steps and parameters remained unchanged.
[0133] Application Example 8
[0134] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 8, and the other steps and parameters remained unchanged.
[0135] Application Example 9
[0136] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 9, and the other steps and parameters remained unchanged.
[0137] Application Example 10
[0138] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 10, and the other steps and parameters remained unchanged.
[0139] Application Example 11
[0140] Compared with Application Example 2-1, the magnetic polyurea microspheres obtained in Example 1 were replaced with the magnetic polyurea microspheres obtained in Example 11, and the other steps and parameters remained unchanged.
[0141] like Figure 4 As shown in B, according to application examples 2-1 and 6-11, the molar amount of hexamethylene diisocyanate in the present invention must be greater than that of propylene diamine, because it can not only polymerize with propylene diamine, but also react with NHS to form NHS active ester. Figure 4 As shown in Figure B, the peak area of the target analyte increases with the increase of the molar ratio of hexamethylene diisocyanate / propylene diamine from 1 to 3, and when the molar ratio increases to 4, the peak area decreases significantly.
[0142] Application Example 3-1
[0143] Compared with Application Example 1, the rat cecal content extract No. 1 in Application Example 1 was replaced with the rat cecal content extract No. 3, and the other steps and parameters remained unchanged.
[0144] Application Example 12
[0145] Compared with Application Example 3-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 12, and the other steps and parameters remained unchanged.
[0146] Application Example 13
[0147] Compared with Application Example 3-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 13, and the other steps and parameters remained unchanged.
[0148] Application Example 14
[0149] Compared with Application Example 3-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 14, and the other steps and parameters remained unchanged.
[0150] Application Example 15
[0151] Compared with Application Example 3-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 15, and the other steps and parameters remained unchanged.
[0152] Application Example 16
[0153] Compared with Application Example 3-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 16, and the other steps and parameters remained unchanged.
[0154] like Figure 4 As shown in Figure C, according to application examples 3-1, 12-16, the magnetic polyurea microspheres prepared by the present invention reach the highest capture efficiency at 0.5 hours, remain stable within 3 hours, and then slightly decrease with time. Considering the robustness of the synthesis process and the low time cost, 1 hour is considered to be the optimal polymerization time for preparing PMMPs.
[0155] Application Example 4-1
[0156] Compared with Application Example 1, the rat cecal content extract No. 1 in Application Example 1 is replaced with the rat cecal content extract No. 4, and the other steps and parameters remain unchanged.
[0157] Application Example 17
[0158] Compared with Application Example 4-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 17, and the other steps and parameters remained unchanged.
[0159] Application Example 18
[0160] Compared with Application Example 4-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 18, and the other steps and parameters remained unchanged.
[0161] Application Example 19
[0162] Compared with Application Example 4-1, the magnetic polyurea microspheres obtained in Example 1 were replaced with the magnetic polyurea microspheres obtained in Example 19, and the other steps and parameters remained unchanged.
[0163] Application Example 20
[0164] Compared with Application Example 4-1, the magnetic polyurea microspheres obtained in Example 1 were replaced by the magnetic polyurea microspheres obtained in Example 20, and the other steps and parameters remained unchanged.
[0165] like Figure 4As shown in D, according to Application Examples 4-1 and 17-20, NHS concentration is the key to synthesizing NHS-activated magnetic polyurea microspheres. Further study on 0.05-0.2M NHS concentration showed that PMMPs synthesized with 0.1M NHS had the best capture efficiency.
[0166] Example 1 Characterization of PMMPs
[0167] The magnetic properties of the magnetic particles were measured using a vibrating sample magnetometer (VSM). Figure 5 As shown in A, the saturation magnetization value of Fe3O4-MNPs prepared by the hydrothermal method is 75.0emu / g. After encapsulation of the polyurea layer, the saturation magnetization value of the prepared PMMPs dropped to 51.6emu / g. NHS ester is the most commonly used amine-specific functional group and is widely used for cross-linking and labeling primary amine ligands. The cross-linking efficiency of NHS esters on the surface of solid materials is generally related to the density of NHS esters, the pH value of the buffer, and stereo issues related to surface interactions. In MES buffer, NHS-activated PMMPs can be efficiently coupled with cystamine dihydrochloride, and the primary amine group at the other end of cystamine can react with the isothiocyanate group of FITC to attach the fluorescent marker to the PMMP. As shown in Figure 5 As shown in Figure B, under a fluorescence microscope, it can be observed that the FITC-labeled PMMPs emit a relatively uniform yellow-green fluorescence at a wavelength of 520 nanometers, indicating that the synthesized PMMPs have good uniformity. Under a laser confocal microscope, it can be observed that the fluorescence is relatively uniformly distributed on the surface of PMMPs, as shown in Figure 2. Figure 5 C, indicating that the spatial distribution of NHS activated esters on the surface of PMMPs is uniform and can effectively covalently link the target ligand.
[0168] The NHS-activated PMMPs were shaken twice in 0.2% ammonia water for 30 minutes each time to release NHS, and then the amount of free NHS in the combined solvent was detected by LC-MS on a HILIC column. Figure 5 D, the calculated density of NHS ester on the PMMPs surface is 1117.8 μmol·g -1 .
[0169] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.
Claims
1. A method for preparing NHS functionalized magnetic material, characterized in that: The steps include: (1) adding a magnetic core material, NHS and a diamine-containing compound into DMF, and then adding a diisocyanate compound solution whose solvent is DMF to mix, thereby obtaining a mixture; In the mixture, the concentration of the magnetic core material is 0.25-4 mg / mL, the concentration of NHS is 0.05-0.2 mol / L, and the molar ratio of the diisocyanate compound to the diamine compound is (1-4):1; (2) The mixture is subjected to an oscillation reaction for 0.5-24 h, the product is separated by a magnet and washed with DMF to obtain an NHS-functionalized magnetic material.
2. The method for preparing a NHS functionalized magnetic material according to claim 1, characterized in that: The diamine-containing compound is one or more of ethylenediamine, propylenediamine, butylenediamine or hexamethylenediamine.
3. The method for preparing a NHS functionalized magnetic material according to claim 1, characterized in that: The diisocyanate-containing compound is one or more of hexamethylene diisocyanate, 1,4-diisocyanate butane, 4,4'-methylene diphenyl diisocyanate, m-xylyl diisocyanate or 1,4-phenylene diisocyanate.
4. The method for preparing a NHS functionalized magnetic material according to claim 1, characterized in that: The magnetic core material is one or more of ferroferric oxide nanoparticles, ferroferric oxide nanoparticles coated with silicon dioxide, ferroferric oxide nanoparticles modified by amino groups or ferroferric oxide nanoparticles modified by carboxyl groups.
5. The method for preparing a NHS functionalized magnetic material according to claim 1, characterized in that: The oscillation reaction time is 0.5-3h, the oscillation reaction temperature is 25°C, and the oscillation frequency is 1500rpm.
6. A NHS functionalized magnetic material prepared by the method according to any one of claims 1 to 5.
7. Use of the NHS functionalized magnetic material according to claim 6 in capturing carboxyl compounds in a sample.
8. The use of the NHS functionalized magnetic material in capturing carboxyl compounds in a sample according to claim 7, characterized in that: It includes the following steps: 1) Cystamine modification: Cystamine dihydrochloride, MES buffer containing Tween-20 and triethylamine are mixed to obtain a cystamine solution, the NHS functionalized magnetic material is dispersed in the cystamine solution, shaken, and washed twice with water and DMF to obtain a cystamine-modified magnetic material; 2) Anhydride modification: the cystamine-modified magnetic material was dispersed in caron anhydride solution, shaken, and washed with DMF three times; 3) EDC / NHS activation: Add a mixed solution of EDC / NHS containing DMF or dichloromethane to the anhydride-modified magnetic material, shake at room temperature, and wash with DMF three times; 4) Diamine modification: the EDC / NHS activated magnetic material is added to DMF for suspension, and then a diamine compound solution containing DMF as solvent is added, and the reaction is shaken at room temperature, and washed twice with water, an acetonitrile aqueous solution containing 0.2 wt% ammonia and 50% acetonitrile volume concentration, and DMF to obtain a magnetic probe; 5) dispersing the magnetic probe in dimethyl sulfoxide and mixing it with the sample to be tested, adding DIPEA and HOBT solutions and mixing, then adding HATU solution and mixing thoroughly, shaking, and then washing twice with 50% acetonitrile aqueous solution and pure acetonitrile respectively; 6) The magnetic probe was redispersed in a 50% acetonitrile aqueous solution, and then a DTT aqueous solution was added. The target analyte, i.e., the carboxyl compound, was released after shaking. The supernatant was collected by magnetic separation, centrifuged, and then subjected to UPLC-Q-TOF-MS / MS detection.
9. The use of the NHS functionalized magnetic material in capturing carboxyl compounds in a sample according to claim 8, characterized in that: The following steps are involved: In step 1), the concentration of cystamine dihydrochloride in the cystamine solution is 0.5-1M, the volume concentration of triethylamine is 5-20%; the concentration of MES buffer is 0.1M, the oscillation reaction time is 5-60min, the oscillation reaction temperature is 25°C, and the oscillation frequency is 1500rpm; In step 2), the concentration of the caron anhydride solution is 0.01-5M, the oscillation reaction time is 5-24h, the oscillation reaction temperature is 25-50°C, and the oscillation frequency is 1500rpm; In step 3), the concentrations of EDC and NHS in the EDC / NHS mixed solution are 0.01-0.1 M, respectively, and the reaction is oscillated at room temperature for 10-24 h at a frequency of 1500 rpm; In step 4), the concentration of the diamine-containing compound is 4 M, and the reaction is oscillated at room temperature for 3-90 min at a frequency of 1500 rpm; In step 5), the concentration of the HOBT solution is 0.05-20 mM, the concentration of the HATU solution is 0.05-20 mM, the oscillation reaction time is 1 h, the oscillation reaction temperature is 25° C., and the oscillation frequency is 1500 rpm; In step 6), the concentration of the DTT aqueous solution is 0.1 M, the oscillation reaction time is 15 min, the oscillation reaction temperature is 25° C., and the oscillation frequency is 1500 rpm.
